- Home
- DJT vs CRNX Comparison
DJT vs CRNX Comparison
Compare DJT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.65
HOLD
Current Price
$53.28
Company Overview
Basic Information| Metric | DJT | CRNX |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DJT | CRNX |
|---|---|---|
| Price | $13.65 | $53.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $71.30 |
| AVG Volume (30 Days) | ★ 17.1M | 1.3M |
| Earning Date | 02-13-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,677,900.00 | $1,535,000.00 |
| Revenue This Year | N/A | $425.41 |
| Revenue Next Year | N/A | $943.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.14 | ★ 47.74 |
| 52 Week Low | $10.18 | $24.10 |
| 52 Week High | $43.46 | $57.99 |
Technical Indicators
Market Signals| Indicator | DJT | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 65.11 |
| Support Level | $12.57 | $43.40 |
| Resistance Level | $14.60 | $57.99 |
| Average True Range (ATR) | 1.14 | 2.82 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 50.35 | 68.49 |
Price Performance
Historical Comparison DJT
CRNX
About DJT Trump Media & Technology Group Corp.
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.